The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Not Open Access | Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester

October 21, 2020 - 09:39 -- NOT Open Access
Author(s): 
Clark RL
Reference: 
Birth Defects Res. 2020 Oct 20

Malaria is a particular problem in pregnancy because of enhanced sensitivity, the possibility of placental malaria, and adverse effects on pregnancy outcome. Artemisinin-containing combination therapies (ACTs) are the most effective antimalarials known. WHO recommends 7-day quinine therapy for uncomplicated Plasmodium falciparum malaria in the first trimester despite the superior tolerability and efficacy of 3-day ACT regimens because artemisinins caused embryolethality and/or cardiovascular malformations at relatively low doses in rats, rabbits, and monkeys.

NOT Open Access | Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia

October 21, 2020 - 09:31 -- NOT Open Access
Author(s): 
Ippolito MM, Pringle JC, Thuma PE, et al.
Reference: 
Am J Trop Med Hyg. 2020 Oct 19

Artemether-lumefantrine (AL) is a first-line agent for uncomplicated malaria caused by Plasmodium falciparum. The WHO recommends periodic therapeutic efficacy studies of antimalarial drugs for the detection of malaria parasite drug resistance and to inform national malaria treatment policies. We conducted a therapeutic efficacy study of AL in a high malaria transmission region of northern Zambia from December 2014 to July 2015.

NOT Open Access | HRP2/3 Mutation in Recrudescent Plasmodium falciparum Malaria Case Acquired in Ethiopia

October 21, 2020 - 08:17 -- NOT Open Access
Author(s): 
Gefen-Halevi S, Belinson V, Manor U, Gazit Z, Smollan G, Belausov N, Biber A, Schwartz E, Grossman T, Leshem E, Amit S
Reference: 
J Travel Med. 2020 Oct 15:taaa196

A 65-year-old Israeli working in Welkait, Ethiopia, not using malaria prophylaxis, developed fever. Malaria RDT was consistent with non-falciparum malaria (plasmodium LDH+/HRP-) but microscopy showed typical P. falciparum.

Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar

September 1, 2020 - 09:43 -- Open Access
Author(s): 
Yanrui Wu, Myat Thut Soe, Pyae Linn Aung, Luyi Zhao, Weilin Zeng, Lynette Menezes, Zhaoqing Yang, Myat Phone Kyaw and Liwang Cui
Reference: 
Malaria Journal 2020 19:304, 27 August 2020

Currently, artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment in malaria-endemic areas. However, resistance in Plasmodium falciparum to artemisinin-based combinations emerging in the Greater Mekong Sub-region is a major problem hindering malaria elimination. To continuously monitor the potential spread of ACT-resistant parasites, this study assessed the efficacy of artemether-lumefantrine (AL) for falciparum malaria in western Myanmar.

NOT Open Access | Retinal involvement in severe noncerebral malaria

August 25, 2020 - 08:21 -- NOT Open Access
Author(s): 
Lando L, Borooah S, Maude RJ
Reference: 
Can J Ophthalmol. 2020 Aug 20:S0008-4182(20)30675-X

A 20-year-old male patient complained of reduced vision after being admitted to a hospital in Bangladesh with 5 days of fever associated with convulsions and anemia (hematocrit 11%). Uncorrected visual acuity was 20/80 OD and 20/64 OS.

Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia

July 14, 2020 - 09:17 -- Open Access
Author(s): 
Abdulhakim Abamecha, Daniel Yilma, Wondimagegn Addisu, Hassan El-Abid, Achim Ibenthal, Harald Noedl, Delenasaw Yewhalaw, Mohieddine Moumni and Alemseged Abdissa
Reference: 
Malaria Journal 2020 19:240, 10 July 2020

The efficacy of artemether-lumefantrine (AL) for treatment of uncomplicated Plasmodium falciparum malaria in south-western Ethiopia is poorly documented. Regular monitoring of drug efficacy is an important tool for supporting national treatment policies and practice. This study investigated the therapeutic efficacy of AL for the treatment of P. falciparum malaria in Ethiopia.

Not Open Access | Artemether-Lumefantrine Efficacy for the Treatment of Uncomplicated Plasmodium falciparum Infection in Choco, Colombia after 8 Years as First-Line Treatment

March 3, 2020 - 12:27 -- NOT Open Access
Author(s): 
Olivera MJ, Guerra AP, Macedo de Oliveira A, et al.
Reference: 
Am J Trop Med Hyg. 2020 Feb 24

Artemether–lumefantrine (AL) is the first-line treatment for uncomplicated Plasmodium falciparum infection in Colombia. To assess AL efficacy for uncomplicated falciparum malaria in Quibdo, Choco, Colombia, we conducted a 28-day therapeutic efficacy study (TES) following the WHO guidelines. From July 2018 to February 2019, febrile patients aged 5–65 years with microscopy-confirmed P. falciparum mono-infection and asexual parasite density of 250–100,000 parasites/µL were enrolled and treated with a supervised 3-day course of AL.

The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

March 2, 2020 - 15:29 -- Open Access
Author(s): 
Bretscher MT, Dahal P, Okell LC, et al.
Reference: 
BMC Med. 2020 Feb 25; 18(1):47

The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ), with amodiaquine being also widely used as part of seasonal malaria chemoprevention programs combined with sulfadoxine-pyrimethamine. While artemisinin derivatives have a short half-life, lumefantrine and amodiaquine may give rise to differing durations of post-treatment prophylaxis, an important additional benefit to patients in higher transmission areas.

A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa

March 2, 2020 - 14:01 -- Open Access
Author(s): 
Onyamboko MA, Hoglund RM, Lee SJ, Kabedi C, Kayembe D, Badjanga BB, Turner GDH, Jackson NV, Tarning J, McGready R, Nosten F, White NJ, Day NPJ, Fanello C
Reference: 
Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e01140-19

Artemether-lumefantrine antimalarial efficacy in pregnancy could be compromised by reduced drug exposure. Population-based simulations suggested that therapeutic efficacy would be improved if the treatment duration was increased. We assessed the efficacy, tolerability, and pharmacokinetics of an extended 5-day regimen of artemether-lumefantrine compared to the standard 3-day treatment in 48 pregnant women and 48 nonpregnant women with uncomplicated falciparum malaria in an open-label, randomized clinical trial. Babies were assessed at birth and 1, 3, 6, and 12 months.

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

February 24, 2020 - 13:42 -- Open Access
Author(s): 
Abdullahi ST, Soyinka JO, Olagunju A, Bolarinwa RA, Olarewaju OJ, Bakare-Odunola MT, Winterberg M, Tarning J, Owen A, Khoo S
Reference: 
Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e00947-19

There is an increased recognition of the need to identify and quantify the impact of genetic polymorphisms on drug-drug interactions. This study investigated the pharmacogenetics of the pharmacokinetic drug-drug interaction between nevirapine and artemether-lumefantrine in HIV-positive and HIV-negative adult Nigerian subjects. Thirty each of HIV-infected patients on nevirapine-based antiretroviral therapy and HIV-negative volunteers without clinical malaria, but with predetermined CYP2B6 c.516GG and TT genotypes, were administered a complete treatment dose of 3 days of artemether-lumefantrine. Rich pharmacokinetic sampling prior to and following the last dose was conducted, and the plasma concentrations of artemether/dihydroartemisinin and lumefantrine/desbutyl-lumefantrine were quantified using tandem mass spectrometry.

Pages

Subscribe to RSS - artemether-lumefantrine